Modulation of RAB7A Protein Expression Determines Resistance to Cisplatin through Late Endocytic Pathway Impairment and Extracellular Vesicular Secretion

Background: Cisplatin (CDDP) is widely used in treatment of cancer, yet patients often develop resistance with consequent therapeutical failure. In CDDP-resistant cells alterations of endocytosis and lysosomal functionality have been revealed, although their causes and contribution to therapy respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Flora, Paiano, Aurora, Migoni, Danilo, Girolimetti, Giulia, Perrone, Anna Myriam, De Iaco, Pierandrea, Fanizzi, Francesco Paolo, Gasparre, Giuseppe, Bucci, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357196/
https://www.ncbi.nlm.nih.gov/pubmed/30626032
http://dx.doi.org/10.3390/cancers11010052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357196/
https://www.ncbi.nlm.nih.gov/pubmed/30626032
http://dx.doi.org/10.3390/cancers11010052

Ejemplares similares